CASTLE ROCK, CO--(Marketwire - October 22, 2008) - AspenBio Pharma, Inc. (NASDAQ: APPY), an emerging bio-pharmaceutical company dedicated to the development of novel drugs and diagnostics for humans and animals, reported the enrollment level in the ongoing FDA 510(k) clinical trial for AppyScore™, the world's first blood-based diagnostic test for human appendicitis, has reached approximately 70%.
